KALA BIO

formerly Kala PharmaceuticalsIPO

KALA BIO is a biotech company in Arlington, United States, founded in 2009. It has raised $113.2M across 4 rounds, most recently a $68.0M Venture Round in April 2016.

Employees
1–10
Founded
2009
Business Model
B2B
Website
kalarx.com
Total Funding
$113.2M
Last Round
$68.0M Venture RoundApr 2016
Rounds
4
Type
Public

Totals include recorded grants and other qualifying funding, not just equity. What counts toward funding.

Indexed holds 4 funding rounds and 7 investors for this company. The full record is or through the API.

About

Kala Pharmaceuticals is a biopharmaceutical company that developed EYSUVIS and INVELTYS, FDA-approved ophthalmic therapies for dry eye disease and postoperative inflammation following ocular surgery, built on its proprietary Ampplify mucus-penetrating particle (MPP) drug delivery technology. The company later sold both commercial products to Alcon as part of its strategic plan to pursue new therapies addressing unmet needs in ophthalmology, a transition that then-CEO Mark Iwicki called an important step for Kala.

Summary

It lists 1–10 employees. It has raised $113.2M in total across 4 rounds, most recently a $68.0M Venture Round in Apr 2016. Investors include Lux Capital, Longitude Capital and OrbiMed.

Tech & App Stack

2 technologies & apps tracked

Every product and vendor across these categories, with where each signal came from.

Create a free account with 25 free credits every month, no card needed, to unlock the full tech & app stack, funding history, and valuations.

Funding & Exit History

Data from Indexed.vcUpdated
IPOJul 2017
$103.5M

Sign up to see all 5 events

Funding: Seed through Venture Round. Amounts, valuations, and investors where available.

Investors

Similar Companies

Sana BiotechnologyIPO

Developer of engineered cells as medicines to treat diseases by repairing or replacing cells for ...

Seattle, United States201–500Biotech, Healthcare
Series DTotal funding$1.4BJun 2020
Altos Labs

Altos Labs combines academic science and industry development to create medicines that restore ce...

San Francisco, United States501–1000Life Sciences, Biotech
Series ATotal funding$3.0BJan 2022
BridgeBioIPO

BridgeBio develops treatments for genetic conditions through autonomous condition-focused teams s...

San Francisco Bay Area, United States201–500Biotech, Healthcare
Growth EquityTotal funding$2.7BJul 2026
AsymchemIPO

Asymchem is a pharmaceutical CDMO providing R&D, chemistry, manufacturing, and control services t...

Tianjin, China5001–10000Biotech, Drug Discovery
Private EquityTotal funding$2.3BFeb 2020
Calico

Calico researches human aging using advanced technologies and model systems, applying that knowle...

South San Francisco, United States201–500Biotech, Healthcare
Corporate RoundTotal funding$2.3BJun 2018
Paratek PharmaceuticalsAcquired

Paratek Pharmaceuticals develops and delivers innovative treatments for serious infectious diseas...

Boston, United States201–500Biotech, Healthcare
ConvertibleTotal funding$1.8BApr 2018

Your company? Embed this profile

Add the live badge to your site — it stays current as your funding data updates.

KALA BIO on Indexed.vc
<a href="https://indexed.vc/companies/kala-bio"><img src="https://indexed.vc/api/badge/company/kala-bio" alt="KALA BIO on Indexed.vc" width="260" height="76" /></a>